论文部分内容阅读
骨和软组织肉瘤病人用化疗或放疗时往往发生恶心和呕吐。近年问世的选择性5-HT3受体拮抗药——康泉(Granisetron)具有明显止呕作用,但康泉主要作用于迷走传入纤维末梢的5-HT3受体,因此应注意康泉对心脏的影响。作者选择12例,其中4例骨肉瘤(OS),4例横纹肌肉瘤,3例恶性纤维组织细胞瘤(MFH),1例Ewing’s肉瘤。治疗前心电图检查正常。OS病人序贯应用大剂量甲氨喋呤(MTX),长春新碱(VCR),顺铂(CDP),吡喃阿霉素(THP)和博莱霉素
Nausea and vomiting often occur in patients with bone and soft tissue sarcoma when treated with chemotherapy or radiation therapy. The selective 5-HT3 receptor antagonist known as Granisetron, which has been available in recent years, has a significant antiemetic effect, but Kangquan mainly acts on the 5-HT3 receptor that vagers the afferent fiber terminals, so care should be taken to the heart of Kangquan. Impact. The authors selected 12 patients, of which 4 were osteosarcoma (OS), 4 were rhabdomyosarcoma, 3 were malignant fibrous histiocytoma (MFH), and 1 was Ewing’s sarcoma. Electrocardiogram was normal before treatment. Large doses of methotrexate (MTX), vincristine (VCR), cisplatin (CDP), pirarubicin (THP) and bleomycin were sequentially administered to OS patients.